An audit of 2609 patient specimens analyzed for both total thyroxine (TT4) and free thyroxine (FT4) by the ACS-180 automated chemiluminescence immunoassay analyzer revealed that there wire 219 discrepancies (8.7% of the total). A discrepancy was defined as one analyte within its reference range and the other outside. The discrepant results were divided into 4 groups: group A: normal TT4, but decreased FT4, 101 patients (4.(P/.); group B: increased TT4, normal FT4, 78 patients (3.1%); group C: decreased TT4, normal FT4, 34 patients (1.4%); and group D: normal TT4, Increased FT4, 8 patients (0.2%). TSH measurements were available, by a 3 "= generation chemiluminascent assay, in t42 of these patients, and ware consistont with the FT4 result in 72 patients, with TT4 in 61 cases and with neither in 9 patients. The clinical diagnosis was investigated in a subgroup of 43 endocrine patients. Thirteen of the 20 endocrine patients in group A ware diagnosed as hypothyroid, with a measured serum TSH, in 11 of them, of median 14.6, range 1.2 to 45.2 idUIml. Eleven of the lS endscrine patients in group B were on thyroid replacement, with a measured serum TSH, in 7 of them of <0.01 idUIml. The audit of current laboratory practice led to a suggestion to replace the current thyroid function screening strategy of measuring both TT4 and FT4 by the combination of FT4 and TSH. The reasons for the discrepancies and the altsmaUve stratagies for scrmming of thyroid function are discussed.
INTRODUCTION
CMC hospital isa referral center for p~ents from all over India. During previous thyroid function investigations in other centers they may have had either total thyroxine (-r-l-4) or free thyroxine (F'I'4) measured and ascedainsd to be almonTml. So as part of a thorough investigation of thyroid function, all specimens sent for thyroid function testing at CMC are analysed for both total ('I-F4) and free thyroxine (FT4). Serum thyroid stimulating hormone (TSH) is only measured when separately requested. It was obsewed that on a number of occasions, the TT4 and FT4 assay results vaere not consistent with one Author for oorrespondance: Dr. J.J. Fleming, at above address. Present address for Prof. A.S. Kanagasabapathy, 205 SMR Krishna, Sikh Road, Secunderabad 5(X)009, Andhra Pradesh another, making the interpretation of the patients' thyroid function very difficult, without the additional measurement of TSH.
Audit in clinical biochemistry may be defined as a process of review and assessment of laboratory performance. The main goal is the improvement of patient care, through improvement of laboratory ~and bet~ use of _r,~,__ _.r~__ (1) . The audit process should lead to definite action to produce a change in practice. It was decided to carry out an audit to determine howwell the serum TT4 and FT4 a~_~.__ys agreed with each other when measured on the same patient specimen.
MATERIALS AND METHODS
All the thyroid function tests were ca~ied out on the Chiren Diagnostics ACS:180 Plus automated chemiluminescence immunoassay analyzer, Ciba Coming diagnostics Corp., MA, USA. Both FT4 and TT4 are competitive immunoassays using direct chemiluminascent technology. The TSH assay uses a two-site sandwich chemiluminescent immunoassay, and is a 3 "= generation assay with a stated sensitivity of 0.011 plUIml. All the results of'l-1"4 and FT4 assays requested onthe same patient specimens, overa nine~ week pedod, were audited. Specimens where either 1-1"4 or FT4 were outside their reference range, while the other was not, were labeled as discrepant.
RESULTS
The quoted reference ranges for 1- figure 1 . About 6.3% of FT4 results were low while the "l-r4 was still nownal (groupA palIem). About 5.0% of TT4 results are above the reference range while the FT4 is still normal (group B pattern).
Over the nine week pedod of the study, a-total of 2509 specimens were analysed for both 17",4 and FT4. There were 219 disczepancies in these 2509 
Group descdpUons as for 
Endocrine patients ofthe tot= endo ne
fell into group A (A3), of these 13 were diagnosed as ~d and 5 v, ere on thyroxine replaeemerr 50-150 i~g/day. Eleven ofthesethirteen had concurrent TSH measurements (median 14.6, range 1.2 to 46.2 i~lUIml). Totally 13 of the 20 patients had a FT4 value of 0.7 ng/ml. TSH (table 2, group A4) was raised in 11 patients, normal in 5 and low in one patient. Three other patients in group A 3 were receiving anti thyroid treatment with carbimazole. One of them had a suppressed TSH (<0.01 !~1U/ml) and the others had a normal TSH. The other patients included one patient with Conn's syndrome, one following thyroid surgery, one with obesity and one with diabetes plus renal failure.
Nineteen of the patients fell into group B (B3).
Eleven of them were on thyroid replacement, ten of these on a dose between 100 to 250 i~g/day, and one on 400 pg/day. Seven of these 11 had concurrent TSH results, (Group EN, all <0.01 idU/ml). Here a suppressed TSH was consistent with a raised "1-1"4. Three other I~ents were on follow up after receiving I '=. Two ottmmwere being treated with carbimazole, one had Graves disease, one was pregnant euthyroid, and one had a TSH producing pituita~j adertoma, (TSH 13.0 FIU/ml). Three endooine patJentsfell into group C (C3), one had pulmonary TB, one treated T3 toxicosis and the other was on replacement therapy with tt~oxine (no TSH result available). Table 2 , group C4, shows that the other two had a normal TSH One endocrine patient came into group D, here the diagnosis was treated Graves disease and the TSH was <0.01 i~lU/ml.
DISCU881ON
The results of "17"4 and FT4 measurements in the same patient are in agreement in 91.3% of the specimens analyzed, but problems of interpretation adse in the other 8.7% of patients. Figure I showing the Chiron data summary, indicateathat the FT4 and 1-1"4 reference range do not completely overlap and this is reflected in the observed discrepancy rate of 4.0 % in group A1 and 3.1% in group B1. Slightly lowering the Io~sr limit of the FT4 range to 0.7 ng/ml will improve the agreement ~ 1-1"4 and FT4 but not improve the agreement between FT4 andTSH results. About 50% of results in group A1 and B1 have one analyte above or beiowits reference range and the other at the upper or lower end, while the other 50% of results are well within the respective reference ranges. So =dight adj~ to either reference range ~II not produce agreement In at leest 50% of the discmpandes. The med(=l history in the subgro~ of mne paUents reve=ed they ~e paUents ~ anU-thyro~ drugs, patiants who had 1131, therapy, or hypothyro~ patients eithor on replacement meraw or not. None ofthem were receiving antJ-convulsant thorapy, belablockers, oestrogen containing preparations or ~,niodarof~ whirl1 are among Ule list of drugs known to diSplacethyr~ne from plasma pr(~n birdng s~s or inhibit r of T4 to T3 (3). This excludes concurrent drug therapy as a cause of the discrepancies found, in them ~ patients but not in the non-andocdne paOer~ forwhacn there ~as no drug his=o~ available.
In non-thyroidal illness (NTI) abnormalities in thyroid function tests are frequently found with a tendency for T'r4 m deanaase and FT4to increase (4). Again NTI was exduded only In our Endocrine patients not in the non-erckcdne ones, In discussing which are the best combinations of tests to screen for thyroid disordors, the greater susceptibility of FT4 assays to assay interference should be morfdoned (5) . Interfering facto~ lnducle the presence in the paUer~s' serum of autom~bodies to T4 and T3, he~rophilic antibodies from inUrnate contact with animals, and human anti-mouse antibodies [HAMA] (6), any of which may ceuse an incorrect F1"4 resdt to be ~.
In inveslJgalion of thyroid r theAmedcan Thyroid Association recommands a strateW of using bcth TSH and an estimate or direct ITmast=~ of FT4 (7). The consensus statement in the UK (8) recommends the use of a combination of sanJm TSH and serum thyroxine to confirm the diagnosis of hypo or hy~.
Many tmspitals in the UK um TSH alone as a first line test with FT4 as a mcorr line tsst when the TSH is abnormal. Hay and Klee (9) re<xxnme~ a third generati~ asiay wllh a lo~qr limit of sensi~ity of 0.01 ~lU/rnlforthis~. ~er memurement of TSH alone may be misleeding in the following circumstances~ hypopituitmlsm, tllyroid hormaue rasisl~e and T~4-1 s~Jng l~mour~ well as NTI. Davey et ai (10) have compemd the measurement of TSH and FT4 in 1000 patient specimens and condude ~ an algordhm ~or b'ly~ furK~on testing based on serum TSH alone, is a relialale indicator of thyrdd function. "rhuslhe IiieraUe suggests that any scman of thyroid function shoukl indude a measummmt of TSH. In our subwoup of Endo~ne paUeres ~ VeaVsd I~t~bm, TSH ~ was not always availaUe ~ the ~ had bean going on forlem ffmn 3 months. In this __r~.~_ the TSH maybe ~II be sUplxam~ while the TT4 or I=I"4 have normalized.
The purpose of an audit in dinlcal biochemistry hsto reviewthe cunant ~ pradi~ to estaUish drawbacks in that current practice, set a standard that may improve performance, knpleme~ it and b~m review the change achieved by the implementation
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(1). The standard that may improve diagnostic performance in screening for thyroid disorders is to include a third generation TSH serum with either the FT4 or TT4 memummerr In ctmosing between TT4 and FT4 assays it is known that using FT4 will eliminate abrmrmalities due to an excess of thyroxine binding protein. There also seems to be a ~ agreement between FT4 and TSH than "I-I'4 and TSH. Therefore the proposal is that the routine screening test for thyroid function should be ctumged to FT4 and a 3n:l generation TSH assay. Since the FT4 and TSH _r~,__,It agreed in 72 out of 142 of the discmpandes (tal01e 2) this would reduce the observed discrepancy rate by about 50%
Regardless of the slmtegy choson there will still be discrepancies between the various test results, which can only be resolved only by further investigations. The investigation and treatment of known thyroid al~ocrnalities may also require further investigation including 3-1"4, T3, thyroglobulin and antithyroid antibody Utres, at the discretion of the treating 1oi~y~cian. In order to implement the ctBnge in screening strategy suggested ideally it would be necessary to confirm the refererme ranges for FT4 and TSH as measured by our current methodology with an optimum number of 125 normal subjects. This is a large 1out necessay expense for any ~ to make when there is uncertainty about the validity of the existing range,~ A fiJrther audit alter a 6-month period would be necessary to review the change achieved by implementation of the new procedure.
